Value of aspartate aminotransferase-to-platelet ratio index, fibrosis-4, and gamma-glutamyl transpeptidase-to-platelet ratio in diagnosis of liver inflammation grade in patients with chronic hepatitis B

Xinlan ZHOU; Xin MA; Yanbing WANG; Xiufen LI; Dan HUANG; Wei LU; Zhanqing ZHANG; Rongrong DING

doi:10.3969/j.issn.1001-5256.2021.09.013

Volume 37 Issue 9

Sep. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(9): 2066-2070

PDF( 2012 KB)

Value of aspartate aminotransferase-to-platelet ratio index, fibrosis-4, and gamma-glutamyl transpeptidase-to-platelet ratio in diagnosis of liver inflammation grade in patients with chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2021.09.013

a.
Department of Hepatobiliary Medicine, Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China
b.
Department of Ultrasound, Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China

Received Date: 2021-01-25
Accepted Date: 2021-03-03
Published Date: 2021-09-20

Abstract

Abstract

Objective To investigate the value of aspartate aminotransferase-to-platelet ratio index (APRI), fibrosis-4 (FIB-4) score, and gamma-glutamyl transpeptidase-to-platelet ratio (GPR) in diagnosis of liver inflammation grade in patients with chronic hepatitis B (CHB). Methods A total of 545 patients with CHB who underwent percutaneous liver biopsy and routine laboratory examinations during hospitalization in Shanghai Public Health Clinical Center Affiliated to Fudan University from October 2016 to October 2019 were enrolled. Inflammation grade (G) was determined according to the Scheuer scoring system, and APRI, FIB-4, and GPR were calculated based on related clinical indicators. The t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between two groups. A Spearman correlation analysis was used to investigate the correlation between two variables. The receiver operating characteristic (ROC) curve was used to evaluate the diagnostic performance of the three serum noninvasive diagnostic models in determining liver inflammation grade, and the Delong test was used for comparison of the area under the ROC curve (AUC). Results Among the 545 patients, 224 had grade G0-1 liver inflammation, 209 had grade G2 liver inflammation, and 112 had grade G3 liver inflammation. The Spearman correlation analysis showed that APRI, FIB-4, and GPR were positively correlated with liver inflammation grade (r=0.611, 0.470, and 0.563, all P < 0.001). APRI, FIB-4, and GPR had an AUC of 0.820, 0.719, and 0.782, respectively, in the diagnosis of G≥2 liver inflammation, with optimal cut-off values of 0.53, 1.48, and 0.20, respectively; for the diagnosis of G≥2 liver inflammation, GPR had a better performance than FIB-4 (P=0.01) and a slightly lower performance than APRI (P=0.048). The stratified analysis based on alanine aminotransferase (ALT) level showed that in the ≤1×upper limit of normal (ULN) group, the (1-2)×ULN group, and the (2-5)×ULN group, APRI had an AUC of 0.847, 0.786, and 0.724, respectively, in the diagnosis of G≥2 liver inflammation, FIB-4 had an AUC of 0.777, 0.729, and 0.626, respectively, and GPR had an AUC of 0.801, 0.781, and 0.607, respectively; the subgroup analysis showed that GPR had a similar diagnostic performance to APRI and FIB-4 in all ALT stratification groups except the (2-5)×ULN group, in which GPR had a lower diagnostic performance than APRI (P=0.042). APRI, FIB-4, and GPR had an AUC of 0.791, 0.725, and 0.801, respectively, in the diagnosis of G≥3 liver inflammation, with optimal cut-off values of 0.66, 1.49, and 0.25, respectively; in the diagnosis of G≥3 liver inflammation, GPR had a similar diagnostic performance to APRI and a better diagnostic performance than FIB-4 (P=0.006). The stratified analysis based on ALT level showed that in the ≤1×ULN group, the (1-2)×ULN group, and the (2-5)×ULN group, APRI had an AUC of 0.900, 0.742, and 0.693, respectively, in the diagnosis of G≥3 liver inflammation, FIB-4 had an AUC of 0.874, 0.683, and 0.644, respectively, and GPR had an AUC of 0.890, 0.805, and 0.668, respectively. The subgroup analysis showed that GPR had a similar diagnostic performance to APRI and FIB-4 in all ALT stratification groups except the (1-2)×ULN group, in which GPR had a better diagnostic performance than FIB-4(P=0.015). Conclusion APRI, FIB-4, and GPR may accurately diagnose liver inflammation grade in CHB patients, which helps to monitor the progression of CHB and determine the timing of antiviral therapy.
- Chronic Hepatits B,
- Inflammation,
- Diagnosis

FullText(HTML)

References(18)

References

[1]	SHIH C, YANG CC, CHOIJILSUREN G, et al. Hepatitis B virus[J]. Trends Microbiol, 2018, 26(4): 386-387. DOI: 10.1016/j.tim.2018.01.009.
[2]	LAMPERTICO P, INVERNIZZI F, VIGANÒ M, et al. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study[J]. J Hepatol, 2015, 63(5): 1118-1125. DOI: 10.1016/j.jhep.2015.06.006.
[3]	KIM WR, LOOMBA R, BERG T, et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B[J]. Cancer, 2015, 121(20): 3631-3638. DOI: 10.1002/cncr.29537.
[4]	KEW MC. Serum aminotransferase concentration as evidence of hepatocellular damage[J]. Lancet, 2000, 355(9204): 591-592. DOI: 10.1016/S0140-6736(99)00219-6.
[5]	NGUYEN MH, GARCIA RT, TRINH HN, et al. Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels[J]. Am J Gastroenterol, 2009, 104(9): 2206-2213. DOI: 10.1038/ajg.2009.248.
[6]	DONG M, WU J, YU X, et al. Validation and comparison of seventeen noninvasive models for evaluating liver fibrosis in Chinese hepatitis B patients[J]. Liver Int, 2018, 38(9): 1562-1570. DOI: 10.1111/liv.13688.
[7]	LEMOINE M, SHIMAKAWA Y, NAYAGAM S, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa[J]. Gut, 2016, 65(8): 1369-1376. DOI: 10.1136/gutjnl-2015-309260.
[8]	WU X, CAI B, SU Z, et al. Aspartate transaminase to platelet ratio index and gamma-glutamyl transpeptidase-to-platelet ratio outweigh fibrosis index based on four factors and red cell distribution width-platelet ratio in diagnosing liver fibrosis and inflammation in chronic hepatitis B[J]. J Clin Lab Anal, 2018, 32(4): e22341. DOI: 10.1002/jcla.22341.
[9]	WANG L, LI J, YANG K, et al. Comparison and evaluation of non-invasive models in predicting liver inflammation and fibrosis of chronic hepatitis B virus-infected patients with high hepatitis B virus DNA and normal or mildly elevated alanine transaminase levels[J]. Medicine (Baltimore), 2020, 99(23): e20548. DOI: 10.1097/MD.0000000000020548.
[10]	Chinese Society of Hepatology and Chinese Society of infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: A 2015 update[J]. J Cin Hepatol, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.
[11]	SCHEUER PJ. The nomenclature of chronic hepatitis: Time for a change[J]. J Hepatol, 1995, 22(1): 112-114. DOI: 10.1016/0168-8278(95)80269-x.
[12]	KOYAMA Y, BRENNER DA. Liver inflammation and fibrosis[J]. J Clin Invest, 2017, 127(1): 55-64. DOI: 10.1172/JCI88881.
[13]	HUANG H, SUN Z, PAN H, et al. Serum metabolomic signatures discriminate early liver inflammation and fibrosis stages in patients with chronic hepatitis B[J]. Sci Rep, 2016, 6: 30853. DOI: 10.1038/srep30853.
[14]	LAI M, HYATT BJ, NASSER I, et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection[J]. J Hepatol, 2007, 47(6): 760-767. DOI: 10.1016/j.jhep.2007.07.022.
[15]	World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection[R]. Geneva: WHO, 2015.
[16]	LIU DP, LU W, ZHANG ZQ, et al. Comparative evaluation of GPR versus APRI and FIB-4 in predicting different levels of liver fibrosis of chronic hepatitis B[J]. J Viral Hepat, 2018, 25(5): 581-589. DOI: 10.1111/jvh.12842.
[17]	LI Q, LI W, HUANG Y, et al. The gamma-glutamyl transpeptidase-to-platelet ratio predicts liver fibrosis and cirrhosis in HBeAg-positive chronic HBV infection patients with high HBV DNA and normal or mildly elevated alanine transaminase levels in China[J]. J Viral Hepat, 2016, 23(11): 912-919. DOI: 10.1111/jvh.12563.
[18]	WANG J, XIA J, YAN X, et al. The gamma-glutamyl transpeptidase to platelet ratio predicts liver inflammation in chronic hepatitis B with normal or mildly elevated alanine transaminase[J]. Clin Res Hepatol Gastroenterol, 2020, 44(6): 913-922. DOI: 10.1016/j.clinre.2020.01.011.

Relative Articles

[1]	Haiyang ZHU, Jingshu CUI, Liu YANG, Mengting ZHOU, Jian TONG, Hongmei HAN. Mechanism of 1，25（OH）₂D₃ improving liver inflammation in a rat model of nonalcoholic steatohepatitis induced by choline-deficient L-amino acid-defined diet[J]. Journal of Clinical Hepatology, 2025, 41(2): 254-262. doi: 10.12449/JCH250210
[2]	Yunchong WU, Yanyan YANG, Chuan LI, Xiaohuan WU, Shide LIN. Role of inflammatory cytokines in disorder of glucose metabolism in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2024, 40(9): 1886-1890. doi: 10.12449/JCH240926
[3]	Zhan ZENG, Yuanjiao GAO, Xiaoyue BI, Fengxin CHEN, Wen DENG, Tingting JIANG, Yanjie LIN, Liu YANG, Minghui LI, Yao XIE. Value of HBsAg level in predicting liver inflammation in patients with HBeAg-positive chronic hepatitis B virus infection and normal alanine aminotransferase[J]. Journal of Clinical Hepatology, 2022, 38(5): 1030-1034. doi: 10.3969/j.issn.1001-5256.2022.05.011
[4]	Huaqian XU, Xue LI, Shanhong TANG. Research advances in the role of inflammatory response and related treatment strategies in acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(8): 1927-1930. doi: 10.3969/j.issn.1001-5256.2022.08.041
[5]	Ting LI, Huabao LIU, Wenyan HU, Chunyan RAO. Role of inflammation in hepatic fibrosis[J]. Journal of Clinical Hepatology, 2022, 38(10): 2368-2372. doi: 10.3969/j.issn.1001-5256.2022.10.032
[6]	Yao LI, Jingchao WANG, Jiaqi YUAN, Hao WEN, Ying ZHOU, Haining FAN, Zhixin WANG. Influence of endoplasmic reticulum stress on the secretion of some inflammatory mediators in hepatic alveolar echinococcosis[J]. Journal of Clinical Hepatology, 2021, 37(1): 131-134. doi: 10.3969/j.issn.1001-5256.2021.01.026
[7]	Wang TingShuai, Wang Na, Zhang RongZhen, Wang MingGang, Huang ShaoDong, Ma YuZhen, Wu Cong, Mao DeWen. Role of immune response and inflammatory injury in the pathogenesis of liver failure[J]. Journal of Clinical Hepatology, 2020, 36(6): 1415-1419. doi: 10.3969/j.issn.1001-5256.2020.06.050
[8]	Yin JinPing, Yue ZiChen, Zhuo ShaoYuan. STAT3: A key molecule in the progression of liver cancer mediated by chronic inflammation[J]. Journal of Clinical Hepatology, 2020, 36(4): 948-952. doi: 10.3969/j.issn.1001-5256.2020.04.054
[9]	Liu Li, Li JunYi, Du YingRong, Huang HongLi, Luo Yu, Li HuiMin, Li WeiKun, Wang Lin, Liu ChunYun. Influencing factors for liver inflammation grade and fibrosis degree in patients with low-level HBV DNA[J]. Journal of Clinical Hepatology, 2019, 35(5): 982-986. doi: 10.3969/j.issn.1001-5256.2019.05.010
[10]	Guo Yan, Huang Li, Yang GuoChao, Liu Shan, Du LinNa, Wang MinJuan. Association between nonalcoholic fatty liver disease and dietary inflammation index and its practical significance[J]. Journal of Clinical Hepatology, 2019, 35(10): 2324-2326. doi: 10.3969/j.issn.1001-5256.2019.10.042
[11]	Ding Jie, Wang Liang, Li Juan, Kong Yin, Zhao Rui, He JingJing, Li GuangMing, Wang JuanXia, Zhang LingYi. Changes in serum asymmetric dimethylarginine levels in progression of liver inflammation in an experimental rat model of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2016, 32(1): 148-151. doi: 10.3969/j.issn.1001-5256.2016.01.029
[12]	Zhu JuanJuan, Cheng MingLiang, Zhao XueKe. Role of liver immunological inflammation in development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2016, 32(3): 570-573. doi: 10.3969/j.issn.1001-5256.2016.03.038
[13]	Li Qiang, Huang YuXian, Chen Liang. Simple serum markers for significant liver inflammation in chronic hepatitis B patients with an alanine aminotransferase level lower than 2 times upper limit of normal[J]. Journal of Clinical Hepatology, 2016, 32(6): 1125-1129. doi: 10.3969/j.issn.1001-5256.2016.06.021
[14]	Wu YuJing, Guo JinSheng. Hepatic stellate cells,Toll-like receptor 4 signaling pathway,and inflammatory fibrotic microenvironment in the development of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(6): 876-879. doi: 10.3969/j.issn.1001-5256.2015.06.012
[15]	Wu YinWei, Wen Jian, Zhao Wei, Zhang Liang, Song YuHua, Tan GuoLei, Zhao Lei. Study on the relationship in peripheral blood lymphocyte subsets and inflammation activity in liver tissue in patients with chronic hepatitis B infection[J]. Journal of Clinical Hepatology, 2008, 24(3): 180-182.
[16]	Xia Qi, Fu JieHai, Cai WeiMin, Liu RongHua. Diagnostic value of AST/PLT and GGT/PLT for hepatic fibrosis.[J]. Journal of Clinical Hepatology, 2007, 23(5): 364-366.
[17]	Dong HongYun, Zhao GuiMing, Li Ying. Study on the relationship between inflammation activity in the liver tissues and expression of HBcAg in patients with chronic hepatits B[J]. Journal of Clinical Hepatology, 2007, 23(1): 13-14.
[18]	Fang Ping, Wu TongSheng. The relation between the effect of lamivudine and inflammation grades in chronic hepatitis B[J]. Journal of Clinical Hepatology, 2003, 19(6): 349-350.

Supplements(0)

Cited By

Cited by

Periodical cited type(16)

1.	余文君，余婷婷，李丽华，王红英，普冬，杨永锐. 血清生物标志物在慢性HBV感染自然史诊断中应用的研究进展. 医学理论与实践. 2025(03): 395-398 .
2.	余文君，余婷婷，李丽华，王红英，普冬. 血清标志物在慢性HBV感染自然史中的诊断价值研究. 大理大学学报. 2025(02): 67-74 .
3.	牛梦铱，杜建新，刘桂玲. 肝纤维化指标、外周血常规指标和GPR对重度慢性乙型肝炎的诊断价值及其相关性分析. 检验医学与临床. 2024(02): 178-182 .
4.	陈媛，徐晶，谌翠容，孙振江，周婧玮. 乙型病毒性肝炎肝硬化患者血清cTNT、LPS水平、FIB-4指数与幽门螺杆菌感染的关系. 中华医院感染学杂志. 2024(07): 998-1001 .
5.	吴旭光，马立华，占国祥，黄志刚. 无创炎症诊断模型在非酒精性脂肪性肝病合并乙型肝炎病毒感染患者肝纤维化诊断中的应用. 中国医师杂志. 2024(02): 245-249 .
6.	赖长祥，唐情容，张秀连，唐奇远，李知玉，周旋，冼文杰，陈瑞坤，吴晓娟，王方. 年龄≤30岁慢性HBV感染者启动抗病毒治疗无创预测模型的构建及分析. 临床肝胆病杂志. 2024(07): 1328-1333 . 本站查看
7.	姚建锋，陈正雷，张煜华. 实时二维超声剪切波弹性成像在慢性乙型肝炎肝纤维化分期中的临床应用. 罕少疾病杂志. 2024(10): 54-56 .
8.	李晓宇，黄秀香，叶迎宾. 血清壳多糖酶3样蛋白1和PLT的比值与FIB-4指数在慢性乙型肝炎轻、中度诊断效价的比较. 标记免疫分析与临床. 2024(09): 1693-1697 .
9.	刘雅茹，胡义扬，赵瑜. 基于证候积分的慢性乙型肝炎湿热证的中西医临床特征. 世界中医药. 2024(22): 3523-3530 .
10.	曾伟梅，董常峰，黄琨，郑保奇，李志艳，冯程，陈昕，刘忠. 声触诊弹性成像线性结合超声评分细分慢性乙肝患者肝纤维化程度. 中华超声影像学杂志. 2023(02): 129-135 .
11.	王娟霞，陈馨悦，魏世博，孙新策，朱浩宇，连唐悠悠，杜雨峰. 慢性乙型肝炎患者肝脏炎症程度预测模型的研究. 中国实用内科杂志. 2023(05): 390-395 .
12.	梁紫茵，周伟泽，黄秀明，邓振雄，利旭辉. 分析基于4项因素的肝纤维化指数值动态变化对恩替卡韦治疗慢性乙型肝炎肝硬化病人患肝癌风险的预测价值. 安徽医药. 2023(06): 1211-1216 .
13.	宋艺佳，刘素彤，张丽慧，赵文霞，刘鸣昊. 无创诊断与代偿期乙型肝炎肝硬化患者中医证型的相关性分析. 中西医结合肝病杂志. 2023(11): 981-985 .
14.	贾梦山，刘加敏，杨艳霞. 血清Galectin-9和PD-L1对慢性乙型肝炎肝脏炎症程度的诊断价值. 分子诊断与治疗杂志. 2022(08): 1354-1357+1362 .
15.	宣佳利. 维生素D对妊娠期高血压大鼠肝脏的保护作用及机制. 牡丹江医学院学报. 2022(05): 10-13 .
16.	黄亮，郑世燕. LSM值、APRI、FIB-4、肝脏病理对肝病诊断运用价值. 中国当代医药. 2022(32): 46-48+57 .

Other cited types(8)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (903) PDF downloads(93)

Value of aspartate aminotransferase-to-platelet ratio index, fibrosis-4, and gamma-glutamyl transpeptidase-to-platelet ratio in diagnosis of liver inflammation grade in patients with chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2021.09.013